For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| OC-01 Low Dose, 0.12 mg/mL | OC-01 0.12 mg/ml nasal spray | 0 | None | 0 | 47 | 33 | 47 | View |
| OC-01 Mid Dose, 0.6 mg/mL | OC-01 0.6 mg/ml nasal spray | 0 | None | 1 | 48 | 44 | 48 | View |
| OC-01 High Dose, 1.2 mg/mL | OC-01 1.2 mg/ml nasal spray | 0 | None | 0 | 44 | 41 | 44 | View |
| Placebo | Vehicle nasal spray | 0 | None | 0 | 43 | 11 | 43 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Anaemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | MedDRA (20.1) | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Conjunctival deposit | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (20.1) | View |
| Visual impairement | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (20.1) | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (20.1) | View |
| Nasal dryness | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (20.1) | View |
| Ocular TEAEs | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (20.1) | View |
| Visual acuity reduced | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (20.1) | View |
| Blepharospasm | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (20.1) | View |
| Conjunctival haemorrhage | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (20.1) | View |
| Eyelid oedema | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (20.1) | View |
| Hordeolum | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (20.1) | View |
| Sneezing | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (20.1) | View |
| Throat irritation | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (20.1) | View |
| Dysaesthesia pharynx | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (20.1) | View |
| Instillation site irritation | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (20.1) | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (20.1) | View |